Are we ready to downregulate mast cells?

Laila Karra*, Beata Berent-Maoz, Micha Ben-Zimra, Francesca Levi-Schaffer

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

53 Scopus citations


Downregulation of mast cells (MCs) function and/or survival is warranted in allergic inflammation (AI), mastocytosis/MC leukemias and in other inflammatory diseases in which MCs have a central role. Human MCs (hMCs) have been recently shown to express the death receptor (DR) TRAIL and the inhibitory receptors (IRs) CD300a and Siglec-8. TRAIL is the only known DR functional on hMCs, and interestingly its function is upregulated by IgE-dependent MC activation. The newly described IRs, CD300a and Siglec-8, potently downregulate MC activation and survival in vitro and inhibit different IgE-mediated responses in vivo. Therefore a selective targeting of TRAIL and of IRs on MC could be a novel immunopharmacological way to downregulate MC-associated diseases.

Original languageAmerican English
Pages (from-to)708-714
Number of pages7
JournalCurrent Opinion in Immunology
Issue number6
StatePublished - Dec 2009

Bibliographical note

Funding Information:
F Levi-Schaffer's research is supported by the Aimwell Charitable Trust (UK) and the Israeli Ministry of Health.


Dive into the research topics of 'Are we ready to downregulate mast cells?'. Together they form a unique fingerprint.

Cite this